Skip to main content
. 2021 Apr 1;9(4):336. doi: 10.3390/vaccines9040336

Figure 1.

Figure 1

Type-specific prevalence with 95% confidence intervals in urine samples from 393 subjects, broken down by cohorts: vaccine-eligible, pre-screening and screening cohorts.